... ," Bloomfield says.
"If confirmed, AML patients in the future will likely be screened for RAS mutations, and those who have one may get high-dose cytarabine for post-remission therapy rather than a ...
... to 4.8 months with best supportive care.
The results show that determining K-Ras ... Belgium will present data on the impact of K-Ras mutations from the Crystal study, in which patients were randomized ...
... the epidermal growth factor receptor (EGFR) mutation.
The Iressa in Non-small cell lung ... patients. In an additional analysis of the biomarkers EGFR and K-ras mutations, the study indicates that both ...
... PI3K inhibition might also block K-Ras-induced tumor development, the investigators also tested ... combination therapy against other models of K-Ras-mutated cancer, including those that involve additional ...
... more evident in the SNU-668 than in the SNU-216 cells. SNU-668 cells demonstrated p53 and ras mutations, and it will be necessary in future studies to clarify the relationship between ...
... aggressive disease that can spread throughout the body. A key molecule in this signaling pathway is RAS, and mutations in it are known to lead to cancer. In some cases, the type of RAS mutation is a ...
...
"This opens the door to using a drug cocktail approach to treat tumors driven by Ras mutations," says Elledge, who is also an investigator with Howard Hughes Medical Institute. "We might be able to ...
... treatment with radiation and have a poor prognosis.
K-RAS mutations lead to the activation of networks, or pathways ... NSCL cancer tumors that harbor K-RAS mutations," Dr. Scaglioni said.
Dr. Scaglioni ...
... previously used two different types of mouse models, one of them with the RAS-mutation and the other with the NF1-mutation. Both mutations individually cause a slowly progressing leukaemia to develop ...
